You are here

Pepaxto

FDA Rescinds Approval of Oncopeptides' Blood Cancer Treatment: Implications and What's Next

Medriva

Mon, 02/26/24 - 10:44 am

Multiple Myeloma

FDA looks to pull approval for Oncopeptides' troubled multiple myeloma drug Pepaxto

Fierce Pharma

Thu, 12/8/22 - 10:01 am

Multiple Myeloma

Oncopeptides Sees Redemption with Positive Multiple Myeloma Data after ODAC Vote

BioSpace

Wed, 10/26/22 - 06:40 pm

clinical trials

relapsed or refractory multiple myeloma

FDA advisory committee issues back to back negative votes on two cancer drugs

MedCity News

Mon, 09/26/22 - 10:31 am

Spectrum Pharmaceuticals

clinical trials

Multiple Myeloma

Despite being approved in Europe, Oncopeptides' Pepaxto will remain sidelined in the US

Fierce Pharma

Sun, 09/25/22 - 02:00 pm

Multiple Myeloma

FDA slams Spectrum and Oncopeptides cancer drugs over efficacy concerns ahead of ODAC meeting

Endpoints

Tue, 09/20/22 - 08:40 pm

Spectrum Pharmaceuticals

Months after pulling only drug from US, Oncopeptides takes back withdrawal request — but stays mum on why

Endpoints

Mon, 01/24/22 - 10:16 am

Multiple Myeloma

Oncopeptides' shares crash as it pulls Pepaxto from the market, plans to shut down commercial units

Fierce Pharma

Sun, 10/24/21 - 10:28 pm